Diabetic Foot, Wounds, Infection Interface, and Multidisciplinary Limb-Preservation Teams

41.1Definition and clinical presentation

The diabetic foot is a recurrent limb-threatening syndrome driven by convergent peripheral neuropathy, ischemia, infection, foot deformity, and impaired wound biology Armstrong et al. (2017). Substantial 5-year mortality follows a first diabetic foot ulcer or major lower-extremity amputation, with survival magnitudes comparable to several common cancers. Consequently, a healed ulcer represents clinical remission rather than definitive cure.

Wound healing requires overlapping phases of hemostasis, inflammation, proliferation, and tissue remodeling; this biologic sequence is interrupted by ischemia, persistent bacterial burden, necrotic tissue, and repetitive mechanical pressure Wound Healing 2019. Principal risk factors for ulceration include peripheral neuropathy, peripheral artery disease (PAD), prior ulceration or amputation, foot deformity, and poor glycemic control DFU Risk Factors 2023.

Presentation encompasses five clinical domains that dictate limb-salvage strategy IWGDF Classification 2019:

• Wound: size, depth, tissue loss, and exposed structures.
• Ischemia: pulses, non-invasive perfusion metrics, and anatomic mapping.
• Infection: local erythema, purulence, and systemic inflammatory signs.
• Pressure: severity of neuropathy, deformity, offloading device fit, and falls risk.
• Host risk: prior ulceration, glycemic control, renal comorbidity, and cardiovascular reserve.

Chronic limb-threatening ischemia (CLTI) is present when peripheral artery disease coexists with rest pain, gangrene, or a lower-limb ulcer present for more than 2 weeks GVG · 2019.

41.2Diagnosis and risk stratification

Multidisciplinary team evaluation is mandatory for patients with PAD presenting with a complex foot threat, CLTI, infection, or ulceration ACC/AHA PAD 2024 · IWGDF Practical 2023. Arterial evaluation follows a stepwise pathway: clinical examination supplemented by ankle-brachial index or toe-brachial index, followed by pedal perfusion testing (toe pressure or transcutaneous oxygen) if initial non-invasive hemodynamics are equivocal, and progressing to anatomic imaging to define a target arterial path for revascularization Intersocietal Guidelines PAD 2023 · IWGDF/ESVS 2023. An ABI of 0.90 or below is diagnostic of PAD; 0.91 to 0.99 is borderline and 1.00 to 1.40 normal, while an ABI above 1.40 or frankly incompressible vessels indicates medial arterial calcinosis and mandates a toe-brachial index (abnormal below 0.70) or transcutaneous oximetry instead. In diabetes, medial arterial calcinosis renders the ankle-brachial index falsely elevated or incompressible and neuropathy blunts ischemic symptoms, mandating early escalation to toe pressure, toe-brachial index, or transcutaneous oximetry.

Risk assessment relies on multiple synergistic classification systems. The Wagner and University of Texas classifications communicate depth, infection, and ischemia; the SINBAD system provides severity scoring and benchmarking DFU Classification Review 2020 · IWGDF Classification 2019. The Wound, Ischemia, and foot Infection (WIfI) classification scores each axis from 0 to 3 to stratify amputation risk and estimate revascularization benefit SVS WIfI 2014. WIfI stage 4 strongly separates amputation risk from earlier stages, yielding a 62.1% amputation rate compared to 6.7% for stages 1 to 3, with an adjusted odds ratio of 10.0 South India WIfI 2025. Anatomic complexity is graded via the Global Limb Anatomic Staging System (GLASS), which evaluates femoropopliteal and infrapopliteal target paths GVG · 2019.

Diabetic foot infection severity grading

Append (O) for osteomyelitis. Demonstrated bone infection without two local inflammatory signs is still classified as 3(O), or 4(O) when at least two SIRS criteria are present. Ischemia can obscure inflammatory findings. The Lavery validation cohort offers separate evidence linking higher severity with hospitalization and amputation; it does not redefine the grades PAD 2007.

Staphylococcus aureus is the central pathogen context in diabetic foot osteomyelitis associated with vascular insufficiency, necessitating targeted evaluation while reserving definitive antimicrobial selection for culture-directed therapy following deep-tissue sampling S. Aureus Osteomyelitis 2015.

41.3Treatment and revascularization pathway

Management integrates offloading, infection source control, and revascularization. For patients with a non-infected, non-ischemic neuropathic plantar forefoot ulcer, first-line therapy is a non-removable knee-high offloading device (total-contact cast or non-removable walker) IWGDF Offloading · 2023. Removable devices are second-line, and surgical offloading (Achilles lengthening, metatarsal head resection, or osteotomy) is reserved for conservative failure.

When revascularization is indicated to restore perfusion for wound healing, the decision between open bypass and endovascular intervention turns on conduit quality, anatomic complexity, and operative fitness. The BEST-CLI trial demonstrated that in patients with CLTI and an adequate single-segment great saphenous vein, a bypass-first strategy yields fewer major adverse limb events or deaths compared with an endovascular-first strategy (42.6% versus 57.4%) BEST-CLI (2022). Free tissue transfer offers a salvage option for complex diabetic lower-limb defects when conventional closure is unattainable and amputation is the alternative Free Tissue Transfer SR 2025. Antibiotic selection, route and duration are detailed in the Antibiotic management subsection of Medical therapy and secondary prevention.

Multidisciplinary limb-preservation treatment logic proceeds sequentially:

1. Grade infection severity and establish immediate source control (abscess drainage, debridement) for severe or deep moderate infections.
2. Evaluate mechanical pressure points and implement non-removable knee-high offloading for stable plantar neuropathic ulcers.
3. Stratify ischemia using WIfI and GLASS; if perfusion limits healing, map the arterial target.
4. Select a revascularization strategy, favoring open bypass in patients with adequate single-segment saphenous vein.
5. Reassess the wound bed post-revascularization for definitive closure, minor amputation, or complex tissue transfer.
6. Institute longitudinal antithrombotic therapy, footwear provision, and surveillance to maintain remission.

41.4Medical therapy and secondary prevention

Antibiotic management of diabetes-related foot infection

Do not prescribe antibiotics for a clinically uninfected ulcer. For infection, obtain an aseptic deep-tissue specimen after cleansing/debridement; obtain bone for culture when osteomyelitis is suspected and sampling is feasible. Do not delay resuscitation, antibiotics and drainage in severe infection to await cultures. Severe infection, or moderate infection with important comorbidity such as PAD, often requires hospitalization. An infected ischemic foot needs urgent joint surgical and vascular assessment to coordinate drainage and revascularization IWGDF/IDSA DFI 2023.

For a mild infection without recent antibiotic exposure in North America or Western Europe, initially cover streptococci and Staphylococcus aureus: a first-generation cephalosporin or antistaphylococcal penicillin is an example when appropriate. Moderate infection may require a beta-lactam/beta-lactamase inhibitor. Ischemic necrosis or gas requires anaerobic as well as Gram-positive/Gram-negative coverage, for example piperacillin/tazobactam or ceftriaxone plus metronidazole. Add MRSA-active treatment when indicated by risk or cultures. These are alternatives, not a combined universal regimen; selection and dosing must account for cultures, local resistance, allergy, renal function and interactions. Routine empirical Pseudomonas coverage is not recommended in temperate climates IWGDF/IDSA DFI 2023.

Use systemic therapy for 1–2 weeks for soft-tissue infection (strong recommendation, high-certainty evidence). An extended course of up to 3–4 weeks may be considered for an extensive infection that is improving but resolving slowly, or when severe PAD is present (conditional, low certainty). Persistent infection after four weeks of apparently appropriate therapy calls for renewed diagnostic and treatment assessment; source control and perfusion need reassessment rather than automatic extension. The small post-debridement 10-versus-20-day trial supports a shorter course in selected moderate/severe soft-tissue infection, not a universal rule IWGDF/IDSA DFI 2023 · PAD 2022.

For osteomyelitis, guideline durations are up to three weeks after minor amputation with a positive bone-margin culture, or six weeks without bone resection/amputation (conditional, low certainty). The three-versus-six-week pilot after surgical debridement used a wide noninferiority margin and does not justify three weeks for all unresected bone infection IWGDF/IDSA DFI 2023 · PAD 2021. Antibiotic-only treatment is a selected forefoot option only when urgent drainage is unnecessary, PAD is absent and bone is not exposed; that exception must not be generalized to ischemic foot infection. Narrow treatment to cultures and change from intravenous to an effective oral regimen once clinical stability and absorption allow. Assess osteomyelitis remission at least six months after antibiotics finish.

Cardiovascular secondary prevention

Post-revascularization medical management targets the persistent cardiovascular and limb-event risk inherent to PAD. In patients undergoing lower-extremity revascularization for symptomatic PAD, the VOYAGER PAD trial showed that antithrombotic therapy with rivaroxaban 2.5 mg twice daily plus aspirin reduces the composite of acute limb ischemia, major vascular amputation, myocardial infarction, ischemic stroke, or cardiovascular death compared to aspirin alone (3-year event rates of 17.3% versus 19.9%; hazard ratio 0.85) VOYAGER PAD · 2020. Diabetes medications warrant specific review; in the CANVAS Program, canagliflozin reduces major cardiovascular events (hazard ratio 0.86) but increases the risk of lower-extremity amputation, primarily at the toe or metatarsal level (6.3 per 1000 patient-years; hazard ratio 1.97) CANVAS Program (2017).

Secondary prevention relies on bundled interventions including structured education, prescription footwear, professional foot care, and routine screening DFU Prevention SR 2016. Surveillance frequency is determined by the categorical risk profile.

41.5Areas of controversy

The efficacy of topical antimicrobial agents for diabetic foot ulcers is not uniformly established. Older low-certainty healing evidence should not be interpreted as an indication to treat infection with topical agents Cochrane Topical Antimicrobials 2017. IWGDF/IDSA 2023 conditionally advises against topical antibiotics added to systemic therapy for soft-tissue infection or osteomyelitis, and against topical antiseptic adjuncts for treating diabetic foot infection IWGDF/IDSA DFI 2023.

The optimal management of falls risk associated with offloading devices is unsettled. While falls are an recognized safety outcome in diabetic foot care, highly heterogeneous study capture limits the establishment of numeric falls-prevention thresholds or specific modification rules for offloading selection Falls DFU Review 2025.

Finally, the integration of machine-learning prediction models into routine revascularization planning is controversial. Although prognostic models for wound healing and limb salvage demonstrate promise, current methodologic heterogeneity confines their clinical application to retrospective audit and quality improvement workflows rather than autonomous prospective treatment selection Machine Learning Limb Salvage 2025.

Further reading

• Free Tissue Transfer for the Management of Diabetic Lower Limb Ulcers: A Systematic Review and Meta-Analysis. (2025). Free-tissue reconstruction for diabetic lower-limb ulcers; a bounded wound-reconstruction topic, not the whole diabetic-foot pathway. Free Tissue Transfer SR 2025